Stefan C. M. Ten Eikelder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stefan C. M. Ten Eikelder has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dick Den Hertog
Amsterdam Business School, University of Amsterdam, 1018 TV Amsterdam, Netherlands
4 shared publications - Thomas Bortfeld
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
4 shared publications - Ali Ajdari
Division of Radiation Biophysics, Department of Radiation Oncology, Massachusetts General Hospital, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA
3 shared publications Dick Den Hertog
Department of Econometrics and Operations Research/ Center for Economic Research (CentER), Tilburg University, Tilburg, NETHERLANDS
1 shared publication- Dimitris Bertsimas
Sloan School of Management, Massachusetts Institute of Technology, Cambridge, USA
1 shared publication - J.H.M. van Amerongen1 shared publication
Latest Publications
- 30 June 2023
- Published by Springer Nature in Mathematical Programming
- Vol. 205 (1-2) , 485-538
Pareto Adaptive Robust Optimality via a Fourier–Motzkin Elimination lens
- 30 June 2023
- Published by Springer Nature in Mathematical Programming
- Vol. 205 (1-2) , 485-538
Pareto Adaptive Robust Optimality via a Fourier–Motzkin Elimination lens
- Open Access
- 31 July 2022
- Published by Elsevier in European Journal of Operational Research
- Vol. 306 (3) , 1170-1185
Resource allocation problems with expensive function evaluations
- 31 July 2022
- Published by Elsevier in European Journal of Operational Research
- Vol. 306 (3) , 1170-1185
Open AccessResource allocation problems with expensive function evaluations
- Open Access
- 7 May 2022
- Published by Springer Nature in Optimization and Engineering
- Vol. 23 (4) , 1949-1986
Adjustable robust treatment-length optimization in radiation therapy
Traditionally, optimization of radiation therapy (RT) treatment plans has been done before the initiation of RT course, using population-wide estimates for patients’ response to therapy. However, recent technological advancements have enabled monitoring individual patient response during the RT course, in the form of biomarkers. Although biomarker data remains subject to substantial uncertainties, information extracted from this data may allow the RT plan to be adapted in a biologically informative way. We present a mathematical framework that optimally adapts the treatment-length of an RT plan based on the acquired mid-treatment biomarker information, while accounting for the inexact nature of this information. We formulate the adaptive treatment-length optimization problem as a 2-stage problem, wherein the information about the model parameters gathered during the first stage influences the decisions in the second stage. Using Adjustable Robust Optimization (ARO) techniques we derive explicit optimal decision rules for the stage-2 decisions and solve the optimization problem. The problem allows for multiple worst-case optimal solutions. To discriminate between these, we introduce the concept of Pareto Adjustable Robustly Optimal solutions. In numerical experiments using lung cancer patient data, the ARO method is benchmarked against several other static and adaptive methods. In the case of exact biomarker information, there is sufficient space to adapt, and numerical results show that taking into account both robustness and adaptability is not necessary. In the case of inexact biomarker information, accounting for adaptability and inexactness of biomarker information is particularly beneficial when robustness (w.r.t. organ-at-risk (OAR) constraint violations) is of high importance. If minor OAR violations are allowed, a nominal folding horizon approach (NOM-FH) is a good performing alternative, which can outperform ARO. Both the difference in performance and the magnitude of OAR violations of NOM-FH are highly influenced by the biomarker information quality.
- 7 May 2022
- Published by Springer Nature in Optimization and Engineering
- Vol. 23 (4) , 1949-1986
Open AccessAdjustable robust treatment-length optimization in radiation therapy
Traditionally, optimization of radiation therapy (RT) treatment plans has been done before the initiation of RT course, using population-wide estimates for patients’ response to therapy. However, recent technological advancements have enabled monitoring individual patient response during the RT course, in the form of biomarkers. Although biomarker data remains subject to substantial uncertainties, information extracted from this data may allow the RT plan to be adapted in a biologically informative way. We present a mathematical framework that optimally adapts the treatment-length of an RT plan based on the acquired mid-treatment biomarker information, while accounting for the inexact nature of this information. We formulate the adaptive treatment-length optimization problem as a 2-stage problem, wherein the information about the model parameters gathered during the first stage influences the decisions in the second stage. Using Adjustable Robust Optimization (ARO) techniques we derive explicit optimal decision rules for the stage-2 decisions and solve the optimization problem. The problem allows for multiple worst-case optimal solutions. To discriminate between these, we introduce the concept of Pareto Adjustable Robustly Optimal solutions. In numerical experiments using lung cancer patient data, the ARO method is benchmarked against several other static and adaptive methods. In the case of exact biomarker information, there is sufficient space to adapt, and numerical results show that taking into account both robustness and adaptability is not necessary. In the case of inexact biomarker information, accounting for adaptability and inexactness of biomarker information is particularly beneficial when robustness (w.r.t. organ-at-risk (OAR) constraint violations) is of high importance. If minor OAR violations are allowed, a nominal folding horizon approach (NOM-FH) is a good performing alternative, which can outperform ARO. Both the difference in performance and the magnitude of OAR violations of NOM-FH are highly influenced by the biomarker information quality.
- 21 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 225016
Conic formulation of fluence map optimization problems
The convexity of objectives and constraints in fluence map optimization (FMO) for radiation therapy has been extensively studied. Next to convexity, there is another important characteristic of optimization functions and problems, which has thus far not been considered in FMO literature: conic representation. Optimization problems that are conically representable using quadratic, exponential and power cones are solvable with advanced primal-dual interior-point algorithms. These algorithms guarantee an optimal solution in polynomial time and have good performance in practice. In this paper, we construct conic representations for most FMO objectives and constraints. This paper is the first that shows that FMO problems containing multiple biological evaluation criteria can be solved in polynomial time. For fractionation-corrected functions for which no exact conic reformulation is found, we provide an accurate approximation that is conically representable. We present numerical results on the TROTS data set, which demonstrate very stable numerical performance for solving FMO problems in conic form. With ongoing research in the optimization community, improvements in speed can be expected, which makes conic optimization a promising alternative for solving FMO problems.
- 21 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 225016
Conic formulation of fluence map optimization problems
The convexity of objectives and constraints in fluence map optimization (FMO) for radiation therapy has been extensively studied. Next to convexity, there is another important characteristic of optimization functions and problems, which has thus far not been considered in FMO literature: conic representation. Optimization problems that are conically representable using quadratic, exponential and power cones are solvable with advanced primal-dual interior-point algorithms. These algorithms guarantee an optimal solution in polynomial time and have good performance in practice. In this paper, we construct conic representations for most FMO objectives and constraints. This paper is the first that shows that FMO problems containing multiple biological evaluation criteria can be solved in polynomial time. For fractionation-corrected functions for which no exact conic reformulation is found, we provide an accurate approximation that is conically representable. We present numerical results on the TROTS data set, which demonstrate very stable numerical performance for solving FMO problems in conic form. With ongoing research in the optimization community, improvements in speed can be expected, which makes conic optimization a promising alternative for solving FMO problems.
- 3 December 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (24) , 245011
Optimal treatment plan adaptation using mid-treatment imaging biomarkers
Previous studies on personalized radiotherapy (RT) have mostly focused on baseline patient stratification, adapting the treatment plan according to mid-treatment anatomical changes, or dose boosting to selected tumor subregions using mid-treatment radiological findings. However, the question of how to find the optimal adapted plan has not been properly tackled. Moreover, the effect of information uncertainty on the resulting adaptation has not been explored. In this paper, we present a framework to optimally adapt radiation therapy treatments to early radiation treatment response estimates derived from pre- and mid-treatment imaging data while considering the information uncertainty. The framework is based on the optimal stopping in radiation therapy (OSRT) framework. Biological response is quantified using tumor control probability (TCP) and normal tissue complication probability (NTCP) models, and these are directly optimized for in the adaptation step. Two adaptation strategies are discussed: (1) uniform dose adaptation and (2) continuous dose adaptation. In the first strategy, the original fluence-map is simply scaled upwards or downwards, depending on whether dose escalation or de-escalation is deemed appropriate based on the mid-treatment response observed from the radiological images. In the second strategy, a full NTCP-TCP-based fluence map re-optimization is performed to achieve the optimal adapted plans. We retrospectively tested the performance of these strategies on 14 canine head and neck cases treated with tomotherapy, using as response biomarker the change in the 3’-deoxy-3’[(18)F]-fluorothymidine (FLT)-PET signals between the pre- and mid-treatment images, and accounting for information uncertainty. Using a 10% uncertainty level, the two adaptation strategies both yield a noteworthy average improvement in guaranteed (worst-case) TCP.
- 3 December 2020
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 65 (24) , 245011
Optimal treatment plan adaptation using mid-treatment imaging biomarkers
Previous studies on personalized radiotherapy (RT) have mostly focused on baseline patient stratification, adapting the treatment plan according to mid-treatment anatomical changes, or dose boosting to selected tumor subregions using mid-treatment radiological findings. However, the question of how to find the optimal adapted plan has not been properly tackled. Moreover, the effect of information uncertainty on the resulting adaptation has not been explored. In this paper, we present a framework to optimally adapt radiation therapy treatments to early radiation treatment response estimates derived from pre- and mid-treatment imaging data while considering the information uncertainty. The framework is based on the optimal stopping in radiation therapy (OSRT) framework. Biological response is quantified using tumor control probability (TCP) and normal tissue complication probability (NTCP) models, and these are directly optimized for in the adaptation step. Two adaptation strategies are discussed: (1) uniform dose adaptation and (2) continuous dose adaptation. In the first strategy, the original fluence-map is simply scaled upwards or downwards, depending on whether dose escalation or de-escalation is deemed appropriate based on the mid-treatment response observed from the radiological images. In the second strategy, a full NTCP-TCP-based fluence map re-optimization is performed to achieve the optimal adapted plans. We retrospectively tested the performance of these strategies on 14 canine head and neck cases treated with tomotherapy, using as response biomarker the change in the 3’-deoxy-3’[(18)F]-fluorothymidine (FLT)-PET signals between the pre- and mid-treatment images, and accounting for information uncertainty. Using a 10% uncertainty level, the two adaptation strategies both yield a noteworthy average improvement in guaranteed (worst-case) TCP.
- 1 March 2019
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (6) , 065011
Optimal combined proton–photon therapy schemes based on the standard BED model
This paper investigates the potential of combined proton–photon therapy schemes in radiation oncology, with a special emphasis on fractionation. Several combined modality models, with and without fractionation, are discussed, and conditions under which combined modality treatments are of added value are demonstrated analytically and numerically. The combined modality optimal fractionation problem with multiple normal tissues is formulated based on the biologically effective dose (BED) model and tested on real patient data. Results indicate that for several patients a combined modality treatment gives better results in terms of biological dose (up to improvement) than single modality proton treatments. For several other patients, a combined modality treatment is found that offers an alternative to the optimal single modality proton treatment, being only marginally worse but using significantly fewer proton fractions, putting less pressure on the limited availability of proton slots. Overall, these results indicate that combined modality treatments can be a viable option, which is expected to become more important as proton therapy centers are spreading but the proton therapy price tag remains high.
- 1 March 2019
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (6) , 065011
Optimal combined proton–photon therapy schemes based on the standard BED model
This paper investigates the potential of combined proton–photon therapy schemes in radiation oncology, with a special emphasis on fractionation. Several combined modality models, with and without fractionation, are discussed, and conditions under which combined modality treatments are of added value are demonstrated analytically and numerically. The combined modality optimal fractionation problem with multiple normal tissues is formulated based on the biologically effective dose (BED) model and tested on real patient data. Results indicate that for several patients a combined modality treatment gives better results in terms of biological dose (up to improvement) than single modality proton treatments. For several other patients, a combined modality treatment is found that offers an alternative to the optimal single modality proton treatment, being only marginally worse but using significantly fewer proton fractions, putting less pressure on the limited availability of proton slots. Overall, these results indicate that combined modality treatments can be a viable option, which is expected to become more important as proton therapy centers are spreading but the proton therapy price tag remains high.